Show Notes
Martin‑Geary AC et al et al., Genome Medicine - A systematic framework to prioritise promoter and UTR variants in 8040 undiagnosed trios from the Genomics England 100,000 Genomes Project, yielding ten likely diagnoses and a validated annotation pipeline for clinical use. Key terms: promoters, untranslated regions, de novo variants, rare disease, Genomics England.
Study Highlights:
The authors applied a region‑specific annotation and strict filtering pipeline to de novo variants in 8040 undiagnosed trios, focusing on proximal promoters and UTRs of dominant disease genes. Eleven candidate de novo variants (twelve total) were prioritised; ten lie in genes that match the proband phenotype and six represent newly identified diagnoses. Validation included RNA‑seq and DNA methylation where available, and pipeline benchmarking against ClinVar showed high specificity. Burden testing in 7862 probands versus matched controls did not show a significant collective enrichment of prioritised promoter/UTR variants.
Conclusion:
Screening proximal promoters and UTRs can uncover additional rare disease diagnoses and the authors provide a high‑specificity framework for clinical pipelines, but routinely including these regions is unlikely to dramatically increase overall diagnostic yield.
QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-05-14.
QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 7
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0
Metadata Audited:
- article_doi
- article_title
- article_journal
- license
Factual Items Audited:
- Framework to identify proximal promoter and UTR variants in known dominant disease genes was developed
- DNVs in 8040 undiagnosed individuals were analyzed; 1311 DNVs in 1118 probands
- Ten likely disease-causing promoter/UTR DNVs in ten individuals; nine prioritized and one SETD5 variant
- Four new diagnoses including SLC2A1, NIPBL, ZBTB18, SETD5; methylation episignature supporting SETD5
- Burden testing did not show significant enrichment of promoter/UTR variants in cases vs controls
- ClinVar analysis shows high specificity; pathogenic variants prioritized ~53.7%; benign ~0.71%
QC result: Pass.
